从循证获益到规范实践：EGFR 突变可切除 NSCLC 术后辅助治疗全程管理要点_腾讯新闻
近年来，表皮生长因子受体（EGFR）突变可切除非小细胞肺癌（NSCLC）的术后辅助...
Case Report: Durable complete response to dual immune checkpoint blockade and EGFR inhibition in microsatellite-stable metastatic duodenal adenocarcinoma
BackgroundSmall bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy with limited treatment options and worse outcomes than colorectal cancer. Wh Abstract Background: Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy with limited treatment options and worse outcomes than colorectal...
Seqera’s Small-Model Approach Tops EGFR Binding Benchmark
According to a recent LinkedIn post from Seqera, its Nextflow Frontier workflow identified small chemistry models that ranked molecules by their likelihood of binding EGFR, a cancer drug target. The post reports a PR-AUC score of 0.887 for 144 molecules,...
HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC
HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC In the phase III HERON-Lung01 trial, ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy and showed a manageable safety profile in patients with EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated...
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression According to results from the phase III SAFFRON trial, the combination of osimertinib and savolitinib significantly improved progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced non–small...
2026 ESMO | PACE-LUNG研究：ctDNA动态监测指导EGFR突变晚期NSCLC一线联合升阶的可行性验证_腾讯新闻
前言近期，在表皮生长因子受体（EGFR）突变（Ex19del/L858R）晚期非小...
Case Report: Longitudinal clonal evolution in EGFR-mutant lung adenocarcinoma with coexisting MET exon 14 skipping and EML4-ALK fusion and subsequent KRAS/BRAF bypass mutations
Abstract Acquired resistance to osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer occurs through on-target mutations or bypass activation of alternative pathways. The longitudinal molecular evolution of a tumor across successive lines of therapy is rarely captured...
Case Report: Long-term survival of a patient with lung adenocarcinoma harboring EGFR 19del/T790M/C797S and KIF26B-NTRK1 rearrangement
Abstract Epidermal growth factor receptor (EGFR) gene mutation stands as one of the most prevalent driver genetic alterations in non-small cell lung cancer (NSCLC). While targeted therapies against EGFR have substantially enhanced patient prognosis, acquired resistance remains a core challenge...
ENPP1 inhibits the cGAS–STING pathway to mediate immune evasion in EGFR-TKI–resistant non–small cell lung cancer
Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated promising clinical efficacy in the treatment of EGFR-mutant non–small cell lung cancer (NSCLC). Despite substantial progress with EGFR-TKIs, the development of acquired resistance remains a major clinical challenge. Notably,...
RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway
Chemoresistance remains a major challenge in the treatment of triple-negative breast cancer (TNBC). However, the mechanisms underlying chemoresistance remain poorly understood. In this study, we identified that higher levels of Rhomboid-Like 2 (RHBDL2) expression were associated with chemoresistance and poor...